4//SEC Filing
Boyle Scott N 4
Accession 0001662579-25-000019
CIK 0001662579other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 4:55 PM ET
Size
13.2 KB
Accession
0001662579-25-000019
Insider Transaction Report
Form 4
Boyle Scott N
Chief Business Officer
Transactions
- Tax Payment
Common Stock
2025-02-13$3.20/sh−1,735$5,552→ 54,832 total - Award
Common Stock
2025-02-14+56,500→ 111,332 total - Sale
Common Stock
2025-02-14$3.15/sh−490$1,544→ 110,842 total - Tax Payment
Common Stock
2025-02-14$3.18/sh−2,368$7,530→ 108,474 total - Sale
Common Stock
2025-02-18$3.15/sh−669$2,107→ 107,805 total - Award
Stock Option (Right to Buy)
2025-02-14+84,700→ 84,700 totalExercise: $3.18Exp: 2035-02-13→ Common Stock (84,700 underlying)
Footnotes (4)
- [F1]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.
- [F2]Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026.
- [F3]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2024.
- [F4]The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.
Documents
Issuer
C4 Therapeutics, Inc.
CIK 0001662579
Entity typeother
Related Parties
1- filerCIK 0001913897
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 4:55 PM ET
- Size
- 13.2 KB